BioAssets: Convergence as Marketing Play
Executive Summary
Most drug and device companies approach convergence as a product development issue--the actual combination in a single product of both device and pharmaceutical attributes. But what if convergence were played out as part of a marketing strategy? That's one of the possibilities being explored by BioAssets, a drug company with a novel approach to the use of TNF inhibitors in spine, who hopes to tap into the strong customer relationships that spine device companies have with surgeons.
You may also be interested in...
At TCT, DES Use and Safety Concerns: Irrational Exuberance or Irrational Anxiety?
Still feeling the reverberations of data released in Barcelona in September, this year's TCT meeting saw session after session on the risks of stent thrombosis from drug-eluting stents. While the data was clear--there is some risk, but not a lot--what to do about it was less clear. And the whole debate raises more questions than answers, for both interventionalists and cardiovascular device companies.
Spinal Concepts: Leading Abbott into the Spine Market
The success of Abbott Laboratories' acquisition of Spinal Concepts may depend as much on company restraint as on company resources.
Convergent Calling: An Interview with Medtronic's Stephen Oesterle
Historic walls between the medical device and biotech sectors are coming down as medical devices incorporate more biologically-active agents as part of their therapy. That's good news for device companies since device technology in these combination devices is every bit as critical to their clinical success as the biologic.